|
Angle PLC on Monday noted the publication of results from a clinical study undertaken with Wilmot Cancer Institute, at the University of Rochester, in New York.
The study used the medical diagnostics company's Parsortix system for cancer detection in 183 women with a pelvic mass, which was caused by benign and malignant conditions.
Parsortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer.
The cells captured from peripheral blood in the Parsortix system were combined with serum protein biomarkers to form a predictive algorithm. The Malignancy Assessment using Gene Identification in Captured Cells algorithm, or MAGIC, proved more successful in the detection of malignancy in women with a pelvic mass than serum biomarkers alone.
Not only did the algorithm detect epithelial ovarian cancer, but also non-ovarian primary cancers and metastatic cancer, the firm said.
‘This research highlights the potential of combining the multiplexed gene analysis of captured cells with serum biomarkers from a simple blood test for rapid and accurate pelvic mass triage. This may help to identify the presence of gynaecological cancers at an earlier stage whilst accurately identifying benign conditions that could be managed locally rather than by a specialist,’ it explains.
The research is now published in the high-impact, peer-reviewed publication Obstetrics & Gynecology.
Shares in the Surrey, England-based company were 1.6% higher at 71.40 pence each in London on Monday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
